<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83045</article-id><article-id pub-id-type="doi">10.7554/eLife.83045</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Efficacy and safety of endocrine therapy after mastectomy in patients with hormone receptor positive breast ductal carcinoma in situ: Retrospective cohort study</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-254347"><name><surname>Niu</surname><given-names>Nan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8206-941X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-254346"><name><surname>Zhang</surname><given-names>Yinan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-293037"><name><surname>Bai</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-260806"><name><surname>Wang</surname><given-names>Xin</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-293038"><name><surname>Yan</surname><given-names>Shunchao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-293039"><name><surname>Song</surname><given-names>Dong</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293040"><name><surname>Xu</surname><given-names>Hong</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293041"><name><surname>Liu</surname><given-names>Tong</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293042"><name><surname>Hua</surname><given-names>Bin</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293043"><name><surname>Zhang</surname><given-names>Yingchao</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293044"><name><surname>Liu</surname><given-names>Jinchi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-217303"><name><surname>Qiao</surname><given-names>Xinbo</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6759-921X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293045"><name><surname>Liu</surname><given-names>Jiaxiang</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-293046"><name><surname>Zheng</surname><given-names>Xinyu</given-names></name><email>xyzheng@cmu.edu.cn</email><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-293047"><name><surname>Cao</surname><given-names>Hongyi</given-names></name><email>caohongyi905@163.com</email><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-156274"><name><surname>Liu</surname><given-names>Caigang</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2083-235X</contrib-id><email>angel-s205@163.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00v408z34</institution-id><institution>Department of Oncology, Shengjing Hospital of China Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Shenyang</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00v408z34</institution-id><institution>Department of Nursing, Shengjing Hospital of China Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Shenyang</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution>Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/034haf133</institution-id><institution>Department of Breast Surgery, the First Hospital of Jilin University</institution></institution-wrap><addr-line><named-content content-type="city">Changchun</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05d659s21</institution-id><institution>Department of Breast Surgery, Liaoning Cancer Hospital and Institute</institution></institution-wrap><addr-line><named-content content-type="city">Shenyang</named-content></addr-line><country>China</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05jscf583</institution-id><institution>Department of Breast Surgery, Cancer Hospital of Harbin Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Harbin</named-content></addr-line><country>China</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jwb5s28</institution-id><institution>Department of General Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03x6hbh34</institution-id><institution>Department of Breast Surgery, the Second Hospital of Jilin University</institution></institution-wrap><addr-line><named-content content-type="city">Changchun</named-content></addr-line><country>China</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wjghj95</institution-id><institution>Department of Breast Surgery, the First Affiliated Hospital of China Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Shenyang</named-content></addr-line><country>China</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wjghj95</institution-id><institution>Department of Pathology, the First Affiliated Hospital of China Medical University and College of Basic Medical Sciences</institution></institution-wrap><addr-line><named-content content-type="city">Shenyang</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Pinder</surname><given-names>Sarah</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>King's College London</institution></institution-wrap><country>United Kingdom</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Ng</surname><given-names>Tony</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>King's College London</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>06</day><month>02</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e83045</elocation-id><history><date date-type="received" iso-8601-date="2022-08-28"><day>28</day><month>08</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-01-15"><day>15</day><month>01</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-10-07"><day>07</day><month>10</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.10.06.22280792"/></event></pub-history><permissions><copyright-statement>© 2023, Niu, Zhang, Bai et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Niu, Zhang, Bai et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83045-v1.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>More than half of Chinese patients with hormone receptor positive (HR+) ductal carcinoma in situ (DCIS) are treated with mastectomy, and usually subjected to postoperative endocrine therapy (ET). Given that long-term ET can cause severe adverse effects it is important to determine the beneficial effect and safety of post-mastectomy ET on the disease-free survival (DFS) and adverse events in patients with HR+ DCIS.</p></sec><sec id="abs2"><title>Methods:</title><p>To explore beneficial effect and safety of post-mastectomy ET in patients with HR+ DCIS, we performed a multicenter, population-based study. This retrospective study analyzed the DFS and adverse events in 1037 HR+ DCIS Chinese patients with or without post-mastectomy ET from eight breast centers between 2006 and 2016. The median follow-up time period was 86 months.</p></sec><sec id="abs3"><title>Results:</title><p>There were 791 DCIS patients receiving ET (ET group). Those patients were followed up for a median of 86 months (range, 60–177 months). There were 23 cases with tumor recurrence or distant metastasis. There were similar 5-year DFS rates and DFS between the ET and non-ET groups, even for those with high-risk factors. Conversely, 37.04% of patients suffered from adverse events after ET, which were significantly higher than those in the non-ET group.</p></sec><sec id="abs4"><title>Conclusions:</title><p>ET after mastectomy did not benefit patients with HR+ DCIS for their DFS, rather increased adverse events in those patients. Therefore, ET after mastectomy may not be recommended for patients with HR+ DCIS, even for those with high-risk factors, such as multifocal, microinvasive, and higher T stage.</p></sec><sec id="abs5"><title>Funding:</title><p>This study was supported by grants from Outstanding Scientific Fund of Shengjing Hospital (201803) and Outstanding Young Scholars of Liaoning Province (2019-YQ-10).</p></sec></abstract><kwd-group kwd-group-type="author-keywords"><kwd>breast ductal carcinoma in situ</kwd><kwd>mastectomy</kwd><kwd>hormone receptor positive</kwd><kwd>endocrine therapy</kwd><kwd>disease-free survival</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Outstanding Young Scholars of Liaoning Province</institution></institution-wrap></funding-source><award-id>2019-YQ-10</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Caigang</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Outstanding Scientific Fund of Shengjing Hospital</institution></institution-wrap></funding-source><award-id>201803</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Caigang</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Endocrine therapy after mastectomy may not be recommended for patients with hormone receptor positive ductal carcinoma in situ, even for those with high-risk factors.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Breast cancer screening in adult women has improved its early detection, increasing incidence of ductal carcinoma in situ (DCIS), which currently accounts for&gt;20% of all new breast cancers in USA (<xref ref-type="bibr" rid="bib11">Ward et al., 2015</xref>; <xref ref-type="bibr" rid="bib9">Siegel et al., 2021</xref>). Breast-conserving surgery (BCS) plus radiotherapy (RT) has been widely used for the control of invasive cancer recurrence (<xref ref-type="bibr" rid="bib8">Shah et al., 2016</xref>). Recent studies have shown that there is an increase in the percentages of DCIS patients for unilateral and bilateral mastectomy in USA, particularly for young patients (<xref ref-type="bibr" rid="bib2">Byun et al., 2021</xref>). There are approximately 30% of DCIS patients receiving mastectomy and potential breast reconstruction, especially for those with widespread, multicentric DCIS in USA (<xref ref-type="bibr" rid="bib12">Wärnberg et al., 2014</xref>; <xref ref-type="bibr" rid="bib13">Worni et al., 2015</xref>). However, there are nearly 60% of DCIS patients receiving mastectomy in China, particularly in the economic underdeveloped regions, because they have a fear of cancer recurrence (FCR) and worry subsequent treatment costs.</p><p>Endocrine therapy (ET) with tamoxifen or aromatase inhibitor (AI) (letrozole, anastrozole, exemestane) has been recommended for hormone receptor positive (HR+) breast cancer patients after BCS plus RT to reduce the risk of contralateral breast cancer (CBC) and ipsilateral breast tumor recurrence by National Comprehensive Cancer Network (<xref ref-type="bibr" rid="bib1">Allred et al., 2012</xref>; <xref ref-type="bibr" rid="bib3">Forbes et al., 2016</xref>; <xref ref-type="bibr" rid="bib4">Ganz et al., 2016</xref>). Premenopausal or perimenopausal patients also receive a subcutaneous injection with goserelin. It is notable that ET after bilateral mastectomy is not recommended for HR+ DCIS patients, who have a minimal risk for disease recurrence. However, ET is still being used for some HR+ DCIS patients post unilateral mastectomy in Western countries because ET has been thought to reduce the risk of contralateral recurrence of invasive and pure DCIS (<xref ref-type="bibr" rid="bib2">Byun et al., 2021</xref>). In China, ET has been widely used for HR+ DCIS patients after mastectomy because of FCR although no specific recommendation of ET for them (<xref ref-type="bibr" rid="bib6">Mao et al., 2021</xref>). Moreover, long-term ET can cause adverse effects, particularly for postmenopausal women. However, there is no report on whether ET after unilateral mastectomy can benefit Chinese HR+ DCIS patients for reducing contralateral recurrence of breast cancer and prolonging disease-free survival (DFS) as well as its safety. Accordingly, this retrospective cohort study evaluated the efficacy and safety of ET after mastectomy in the DFS and adverse events of 1037 HR+ DCIS patients.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2-1"><title>Subjects</title><p>This study was approved by the Institutional Review Board of Shengjing Hospital (approval number: 2020PS014K). This retrospective cohort study reviewed and analyzed the DFS and adverse events in 1037 HR+ DCIS patients with, or without, ET after mastectomy from December 2006 to August 2016 (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The inclusion criteria included: (1) age &gt;18; (2) pathological diagnosis of estrogen receptor low-positive (1–10% nuclei staining) and positive (&gt;10% nuclei staining, using methodology outlined in the ASCO/CAP HR testing guideline) DCIS regardless of progesterone receptor expression and Her-2 status; (3) receiving mastectomy regardless of treatment with ET; (4) complete medical records with regular postoperative follow-up for at least for 5 years.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Flowchart of the study.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83045-fig1-v1.tif"/></fig></sec><sec id="s2-2"><title>Data collection and statistical analysis</title><p>The demographic and clinical data, including age, menopausal status, diagnosis, tumor pathological index, adjuvant treatments (drugs, duration), the ET-related adverse effects, tumor recurrence, and survival status were collected by reviewing the case notes and follow-up records. The tumor recurrence was defined as pathologically confirmed breast cancer (DCIS, invasive breast cancer) or metastatic cancers. The DFS was calculated from the diagnosis to the tumor recurrence, or the last follow-up.</p><p>All patients were stratified, based on ET, and their demographic and clinical data were analyzed by Chi-squared, Fisher’s exact, and Wilcoxon rank sum tests where applicable. Their DFS was estimated using Kaplan-Meier method and analyzed by the log-rank test. The potential risk of individual factors for the tumor recurrence was analyzed by hazard ratios and 95% confidence intervals. All statistical analyses were performed by SPSS 24.0 software (SPSS, Chicago, IL, USA). Statistical significance was defined when a two-tailed p-value is &lt;0.05.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>ET after mastectomy does not significantly alter the DFS of HR+ DCIS patients</title><p>A total of 1007 HR+ DCIS patients with mastectomy were selected and their demographic and clinical data are shown in <xref ref-type="table" rid="table1">Table 1</xref>. According to ET treatment, those patients were stratified in the ET (n=791) and non-ET (n=216) groups. There was no significant difference in any of the demographic and clinical measures tested between these two groups. There were 23 cases (19 vs. 4 between the ET and non-ET groups) with tumor recurrence, leading to 2.40% vs. 1.85% (p&gt;0.05, determined by Fisher’s exact test) of tumor recurrence rate in the ET and non-ET groups throughout the 12-year postsurgical observation (<xref ref-type="table" rid="table2">Table 2</xref>). There were 4 cases with invasive local recurrence, 3 with CBC, 12 with distant metastasis in the ET group while 4 cases with distant metastases in the non-ET group. Stratification analyses indicated that the tumor recurrence rate was not significantly associated with these measures, including high-risk factors in this population and surgery methods (unilateral mastectomy or bilateral mastectomy) (p&gt;0.05 for all, <xref ref-type="table" rid="table3">Table 3</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>The demographic and clinical characteristics of patients.</title><p><supplementary-material id="table1sdata1"><label>Table 1—source data 1.</label><caption><title>The demographic and clinical characteristics of patients.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83045-table1-data1-v1.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="center" valign="bottom">ET (N=791)</th><th align="center" valign="bottom">Non-ET (N=216)</th><th align="center" valign="bottom">p-Value</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>Age (n, %</bold>)</td><td align="center" valign="bottom"/><td align="center" valign="bottom"/><td align="center" valign="bottom">0.134</td></tr><tr><td align="char" char="." valign="bottom">≤50</td><td align="center" valign="bottom">448 (57%)</td><td align="center" valign="bottom">110 (51%)</td><td align="center" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">&gt;50</td><td align="center" valign="bottom">343 (43%)</td><td align="center" valign="bottom">106 (49%)</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom"><bold>Tumor size (n, %</bold>)</td><td align="center" valign="bottom"/><td align="center" valign="bottom"/><td align="center" valign="bottom">0.839</td></tr><tr><td align="char" char="." valign="bottom">≤20 mm</td><td align="center" valign="bottom">459 (58%)</td><td align="center" valign="bottom">127 (59%)</td><td align="center" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">&gt;20 mm</td><td align="center" valign="bottom">332 (42%)</td><td align="center" valign="bottom">89 (41%)</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom"><bold>Microinvasive (n, %</bold>)</td><td align="center" valign="bottom"/><td align="center" valign="bottom"/><td align="center" valign="bottom">0.322</td></tr><tr><td align="left" valign="bottom">Yes</td><td align="center" valign="bottom">128 (16%)</td><td align="center" valign="bottom">29 (13%)</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom">No</td><td align="center" valign="bottom">663 (84%)</td><td align="center" valign="bottom">187 (87%)</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom"><bold>Tumor grade (n, %</bold>)</td><td align="center" valign="bottom"/><td align="center" valign="bottom"/><td align="center" valign="bottom">0.190</td></tr><tr><td align="left" valign="bottom">I-II</td><td align="center" valign="bottom">565 (71%)</td><td align="center" valign="bottom">164 (76%)</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom">III</td><td align="center" valign="bottom">226 (29%)</td><td align="center" valign="bottom">52 (24%)</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom"><bold>Ki67 (n, %</bold>)</td><td align="center" valign="bottom"/><td align="center" valign="bottom"/><td align="center" valign="bottom">0.071</td></tr><tr><td align="char" char="." valign="bottom">≥15%</td><td align="center" valign="bottom">279 (35%)</td><td align="center" valign="bottom">62 (29%)</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom">＜15%</td><td align="center" valign="bottom">512 (65%)</td><td align="center" valign="bottom">154 (71%)</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom"><bold>Multifocal (n, %</bold>)</td><td align="center" valign="bottom"/><td align="center" valign="bottom"/><td align="center" valign="bottom">0.310</td></tr><tr><td align="left" valign="bottom">Yes</td><td align="center" valign="bottom">64 (8%)</td><td align="center" valign="bottom">13 (6%)</td><td align="center" valign="bottom"/></tr><tr><td align="left" valign="bottom">No</td><td align="center" valign="bottom">727 (92%)</td><td align="center" valign="bottom">203 (94%)</td><td align="center" valign="bottom"/></tr></tbody></table><table-wrap-foot><fn><p>Notes: Data are n (%). ET, endocrine therapy. Source files available in <xref ref-type="supplementary-material" rid="table1sdata1">Table 1—source data 1</xref>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Tumor recurrence rates in patients with HR+ DCIS after mastectomy.</title><p><supplementary-material id="table2sdata1"><label>Table 2—source data 1.</label><caption><title>Tumor recurrences in patients with hormone receptor positive (HR+) ductal carcinoma in situ (DCIS) after mastectomy.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83045-table2-data1-v1.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Tumor recurrence</th><th align="center" valign="bottom">ET (N=19)</th><th align="center" valign="bottom">Non-ET (N=4)</th></tr></thead><tbody><tr><td align="left" valign="bottom">Invasive local recurrence</td><td align="center" valign="bottom">4 (21%)</td><td align="center" valign="bottom">0 (0%)</td></tr><tr><td align="left" valign="bottom">Contralateral breast cancer</td><td align="center" valign="bottom">3 (16%)</td><td align="center" valign="bottom">0 (0%)</td></tr><tr><td align="left" valign="bottom"><bold>Distant metastasis</bold></td><td align="center" valign="bottom"> </td><td align="center" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Bone</td><td align="center" valign="bottom">6 (32%)</td><td align="center" valign="bottom">1 (25%)</td></tr><tr><td align="left" valign="bottom">Liver</td><td align="center" valign="bottom">2 (11%)</td><td align="center" valign="bottom">2 (50%)</td></tr><tr><td align="left" valign="bottom">Lung</td><td align="center" valign="bottom">1 (5%)</td><td align="center" valign="bottom">0 (0%)</td></tr><tr><td align="left" valign="bottom">Brain</td><td align="center" valign="bottom">1 (5%)</td><td align="center" valign="bottom">0 (0%)</td></tr><tr><td align="left" valign="bottom">Abdominal cavity</td><td align="center" valign="bottom">1 (5%)</td><td align="center" valign="bottom">1 (25%)</td></tr><tr><td align="left" valign="bottom">Lymph nodes</td><td align="center" valign="bottom">1 (5%)</td><td align="center" valign="bottom">0 (0%)</td></tr></tbody></table><table-wrap-foot><fn><p>Notes: Data are n (%). HR, hormone receptor; DCIS, ductal carcinoma in situ; ET, endocrine therapy.</p></fn><fn><p>Source files available in <xref ref-type="supplementary-material" rid="table2sdata1">Table 2—source data 1</xref>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Stratification analysis of tumor recurrence rates in patients with HR+ DCIS after mastectomy.</title><p><supplementary-material id="table3sdata1"><label>Table 3—source data 1.</label><caption><title>Tumor recurrences in subgroups.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83045-table3-data1-v1.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Characteristic</th><th align="left" valign="bottom">ET (N=791)</th><th align="left" valign="bottom">Non-ET (N=216)</th><th align="left" valign="bottom">HR (95% CI)</th><th align="left" valign="bottom">p-Value</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>Total</bold></td><td align="char" char="." valign="bottom">19 (791)</td><td align="char" char="." valign="bottom">4 (216)</td><td align="char" char="." valign="bottom">1.30 (0.48–3.52)</td><td align="char" char="." valign="bottom">0.64</td></tr><tr><td align="left" valign="bottom"><bold>Age</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">≤50</td><td align="char" char="." valign="bottom">12 (448)</td><td align="char" char="." valign="bottom">1 (110)</td><td align="char" char="." valign="bottom">2.91 (0.74–11.47)</td><td align="char" char="." valign="bottom">0.28</td></tr><tr><td align="char" char="." valign="bottom">&gt;50</td><td align="char" char="." valign="bottom">7 (343)</td><td align="char" char="." valign="bottom">3 (106)</td><td align="char" char="." valign="bottom">0.75 (0.18–3.17)</td><td align="char" char="." valign="bottom">0.67</td></tr><tr><td align="left" valign="bottom"><bold>Tumor size</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">≤20 mm</td><td align="char" char="." valign="bottom">6 (459)</td><td align="char" char="." valign="bottom">2 (127)</td><td align="char" char="." valign="bottom">0.82 (0.15–4.44)</td><td align="char" char="." valign="bottom">0.81</td></tr><tr><td align="char" char="." valign="bottom">&gt;20 mm</td><td align="char" char="." valign="bottom">13 (332)</td><td align="char" char="." valign="bottom">2 (89)</td><td align="char" char="." valign="bottom">1.75 (0.51–6.04)</td><td align="char" char="." valign="bottom">0.45</td></tr><tr><td align="left" valign="bottom"><bold>Microinvasive</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">8 (128)</td><td align="char" char="." valign="bottom">0 (29)</td><td align="char" char="." valign="bottom">3.48 (0.60–20.02)</td><td align="char" char="." valign="bottom">0.16</td></tr><tr><td align="left" valign="bottom">No</td><td align="char" char="." valign="bottom">11 (663)</td><td align="char" char="." valign="bottom">4 (187)</td><td align="char" char="." valign="bottom">0.76 (0.22–2.59)</td><td align="char" char="." valign="bottom">0.64</td></tr><tr><td align="left" valign="bottom"><bold>Tumor grade</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">I-II</td><td align="char" char="." valign="bottom">10 (565)</td><td align="char" char="." valign="bottom">0 (164)</td><td align="char" char="." valign="bottom">3.64 (0.82–16.06)</td><td align="char" char="." valign="bottom">0.09</td></tr><tr><td align="left" valign="bottom">III</td><td align="char" char="." valign="bottom">9 (226)</td><td align="char" char="." valign="bottom">4 (52)</td><td align="char" char="." valign="bottom">0.51 (0.13–2.07)</td><td align="char" char="." valign="bottom">0.26</td></tr><tr><td align="left" valign="bottom"><bold>ER</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="char" char="ndash" valign="bottom">1–10%</td><td align="char" char="." valign="bottom">4 (165)</td><td align="char" char="." valign="bottom">2 (40)</td><td align="char" char="." valign="bottom">0.47 (0.08–2.67)</td><td align="char" char="." valign="bottom">0.386</td></tr><tr><td align="char" char="." valign="bottom">&gt;10%</td><td align="char" char="." valign="bottom">15 (626)</td><td align="char" char="." valign="bottom">2 (176)</td><td align="char" char="." valign="bottom">2.14 (0.48–9.43)</td><td align="char" char="." valign="bottom">0.305</td></tr><tr><td align="left" valign="bottom"><bold>Ki67</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="char" char="." valign="bottom">≥15%</td><td align="char" char="." valign="bottom">7 (279)</td><td align="char" char="." valign="bottom">1 (62)</td><td align="char" char="." valign="bottom">0.88 (0.09–8.29)</td><td align="char" char="." valign="bottom">0.67</td></tr><tr><td align="left" valign="bottom">＜15%</td><td align="char" char="." valign="bottom">12 (512)</td><td align="char" char="." valign="bottom">3 (154)</td><td align="char" char="." valign="bottom">1.42 (0.46–4.38)</td><td align="char" char="." valign="bottom">0.74</td></tr><tr><td align="left" valign="bottom"><bold>Multifocal</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Yes</td><td align="char" char="." valign="bottom">3 (64)</td><td align="char" char="." valign="bottom">0 (13)</td><td align="char" char="." valign="bottom">3.34 (0.17–67.46)</td><td align="char" char="." valign="bottom">0.43</td></tr><tr><td align="left" valign="bottom">No</td><td align="char" char="." valign="bottom">16 (727)</td><td align="char" char="." valign="bottom">4 (203)</td><td align="char" char="." valign="bottom">1.11 (0.38–3.22)</td><td align="char" char="." valign="bottom">0.85</td></tr><tr><td align="left" valign="bottom"><bold>Surgery</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Unilateral mastectomy</td><td align="char" char="." valign="bottom">19 (776)</td><td align="char" char="." valign="bottom">4 (215)</td><td align="char" char="." valign="bottom">1.32 (0.45–3.93)</td><td align="char" char="." valign="bottom">0.61</td></tr><tr><td align="left" valign="bottom">Bilateral mastectomy</td><td align="char" char="." valign="bottom">0 (15)</td><td align="char" char="." valign="bottom">0 (1)</td><td align="left" valign="bottom">–</td><td align="left" valign="bottom">–</td></tr></tbody></table><table-wrap-foot><fn><p>Notes: HR, hormone receptor; DCIS, ductal carcinoma in situ; ET, endocrine therapy.</p></fn><fn><p>Source files available in <xref ref-type="supplementary-material" rid="table3sdata1">Table 3—source data 1</xref>.</p></fn></table-wrap-foot></table-wrap><p>There was no significant difference in the percentages of patients with a 5-year DFS rate of 98.36% vs. 99.07% between the ET and non-ET groups (p=0.44, <xref ref-type="fig" rid="fig2">Figure 2A</xref>). Further analysis revealed that there was also no significant difference in the percentages of patients with DFS between these subgroups (p&gt;0.05 for all, <xref ref-type="fig" rid="fig2">Figure 2B–F</xref>), suggesting that the age, larger tumor size, positive microinvasive, higher tumor grade, and Ki67 levels were not associated with increased risk of worse DFS in this population. Hence, ET after mastectomy did not significantly reduce the tumor recurrence rate and prolong the DFS in HR+ DCIS patients.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>The DFS of HR+ DCIS patients with or without post-mastectomy ET.</title><p>Kaplan-Meier analysis indicated that there was no significant difference in the DFS of HR+ DCIS patients between those with and without post-mastectomy ET. (<bold>A</bold>) There was no significant difference in the DFS of HR+ DCIS patients with age &lt;50, (<bold>B</bold>) a larger tumor, (<bold>C</bold>) positive microinvasive, (<bold>D</bold>) higher tumor grade, (<bold>E</bold>) higher Ki67 level, (<bold>F</bold>) between those with and without post-mastectomy ET. HR, hormone receptor; DCIS, ductal carcinoma in situ; ET, endocrine therapy; DFS, disease-free survival. Source files available in <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>The disease-free survival of hormone receptor positive (HR+) ductal carcinoma in situ (DCIS) patients between endocrine therapy (ET) and non-ET groups.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83045-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83045-fig2-v1.tif"/></fig></sec><sec id="s3-2"><title>The ET-related adverse effects</title><p>ET can cause musculoskeletal dysfunction, vasomotor symptoms, gynecological events, cardiovascular events, and abnormal liver function in women, particularly in postmenopausal women. There were 551 patients receiving tamoxifen, 223 with AI, and others beginning with tamoxifen and later switching to AI. Analysis of adverse events in both groups revealed that 37.04% of patients in the ET group developed at least one adverse event, including bone fracture or endometrial cancer (n=4 each), while 15.28% of cases with these events in the non-ET group. There were 14.54% of patients with musculoskeletal dysfunctions, such as arthralgia, joint stiffness, osteoporosis, or myalgia in the ET group and the percentages of some adverse events tested in the ET group were significantly higher than that in the non-ET group in this population (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Adverse events between tamoxifen and AI in the ET group are shown in <xref ref-type="table" rid="table4">Table 4</xref>.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>The frequency of patients with adverse effects between the ET and non-ET groups.</title><p>Data are expressed as % of cases with adverse events and real case numbers labeled and analyzed by Chi-squared test. *p&lt;0.05, ***p&lt;0.001. ET, endocrine therapy. Source files available in <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Adverse events between the endocrine therapy (ET) and non-ET groups.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83045-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83045-fig3-v1.tif"/></fig><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Adverse events between TAM and AI in the ET group.</title><p><supplementary-material id="table4sdata1"><label>Table 4—source data 1.</label><caption><title>Adverse events in the endocrine therapy (ET) group.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83045-table4-data1-v1.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Adverse events</th><th align="left" valign="bottom">TAM (N=551)</th><th align="left" valign="bottom">AI (N=223)</th></tr></thead><tbody><tr><td align="left" valign="bottom">Total</td><td align="char" char="." valign="bottom">212 (38%)</td><td align="char" char="." valign="bottom">76 (34%)</td></tr><tr><td align="left" valign="bottom">Musculoskeletal symptoms</td><td align="char" char="." valign="bottom">61 (11%)</td><td align="char" char="." valign="bottom">52 (23%)</td></tr><tr><td align="left" valign="bottom">Vasomotor symptoms</td><td align="char" char="." valign="bottom">42 (8%)</td><td align="char" char="." valign="bottom">12 (5%)</td></tr><tr><td align="left" valign="bottom">Gynecological events</td><td align="char" char="." valign="bottom">113 (21%)</td><td align="char" char="." valign="bottom">5 (2%)</td></tr><tr><td align="left" valign="bottom">Cardiovascular events</td><td align="char" char="." valign="bottom">26 (5%)</td><td align="char" char="." valign="bottom">12 (5%)</td></tr><tr><td align="left" valign="bottom">Abnormal liver function</td><td align="char" char="." valign="bottom">10 (2%)</td><td align="char" char="." valign="bottom">4 (2%)</td></tr></tbody></table><table-wrap-foot><fn><p>Notes: TAM, tamoxifen; AI, aromatase inhibitor; ET, endocrine therapy.</p></fn><fn><p>Source files available in <xref ref-type="supplementary-material" rid="table4sdata1">Table 4—source data 1</xref>.</p></fn></table-wrap-foot></table-wrap><p>Therefore, ET after mastectomy was associated with increased risk for development of different types of adverse effects in patients with HR+ DCIS.</p></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>Therapeutic strategies for HR+ DCIS, including mastectomy or BCS plus RT, have achieved a similarly high survival rate in patients (<xref ref-type="bibr" rid="bib5">Mannu et al., 2020</xref>; <xref ref-type="bibr" rid="bib7">Narod et al., 2015</xref>). Although ET after BCS plus RT is recommended for patients with HR+ DCIS, and benefits for those with positive surgical margin (<xref ref-type="bibr" rid="bib1">Allred et al., 2012</xref>; <xref ref-type="bibr" rid="bib3">Forbes et al., 2016</xref>; <xref ref-type="bibr" rid="bib4">Ganz et al., 2016</xref>; <xref ref-type="bibr" rid="bib10">Wapnir et al., 2011</xref>), many Asian HR+ DCIS patients chose mastectomy and received ET (<xref ref-type="bibr" rid="bib6">Mao et al., 2021</xref>; <xref ref-type="bibr" rid="bib13">Worni et al., 2015</xref>). In the present study, 78.55% of HR+ DCIS patients were treated with post-mastectomy ET. More importantly, we found that there was no significant difference in a 5-year DFS rate and tumor recurrence rate in HR+ DCIS patients regardless of ET, even in those with high-risk factors for tumor recurrence. The proportion with microinvasive was 16% in the ET group, and 13% in the non-ET group, respectively. Further analysis indicated that patients with high grade of DCIS in the microinvasive subgroup accounted for 42% and 10% in the ET group and non-ET group, respectively. This might explain why the DFS of those with microinvasive DCIS in the ET group trended to be worse than those in the non-ET group although there was no significant difference between them.</p><p>To the best of our knowledge, this was the first report on the efficacy of ET after mastectomy in the DFS of Chinese HR+ DCIS patients and these novel findings clearly indicated that ET after mastectomy did not prolong the DFS of HR+ DCIS patients.</p><p>Long-term ET can cause multiple adverse effects, affecting the life quality of patients. Indeed, 37.04% of patients developed adverse events following ET. Quantitative analysis revealed that the percentages of patients with musculoskeletal dysfunction, gynecological events, and abnormal liver function, but not vasomotor symptoms and cardiovascular events, in the ET group were significantly higher than that in the non-ET group of patients. The increased percentages of patients with these clinical symptoms demonstrated that long-term ET caused multiple adverse effects in HR+ DCIS patients after mastectomy. Given that the majority of HR+ DCIS patients chose mastectomy with a long DFS and ET after mastectomy did not prolong their DFS, rather significantly increased ET-related adverse effects in those patients, our findings suggest that ET may be decreased for its dose and duration or completely avoided for HR+ DCIS patients following mastectomy to improve their life quality.</p><p>We recognized that our study was retrospective in nature and with a small number of events. Further validation of these findings is warranted in a large, randomized prospective trial to better understand the benefits and toxicities of ET in HR+ DCIS patients and inform future care.</p><sec id="s4-1"><title>Conclusions</title><p>ET after mastectomy did not prolong the DFS of HR+ DCIS patients, rather increased adverse effects. Therefore, ET may be decreased for its dose and duration or completely avoided for HR+ DCIS patients after mastectomy.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>Senior editor, <italic>eLife</italic></p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Resources, Formal analysis, Writing – original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Resources, Data curation, Formal analysis</p></fn><fn fn-type="con" id="con3"><p>Resources, Data curation</p></fn><fn fn-type="con" id="con4"><p>Resources, Data curation</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Writing – original draft</p></fn><fn fn-type="con" id="con6"><p>Resources, Data curation</p></fn><fn fn-type="con" id="con7"><p>Resources, Data curation</p></fn><fn fn-type="con" id="con8"><p>Resources, Data curation</p></fn><fn fn-type="con" id="con9"><p>Resources, Data curation</p></fn><fn fn-type="con" id="con10"><p>Resources, Data curation</p></fn><fn fn-type="con" id="con11"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con12"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con13"><p>Resources, Data curation</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Supervision, Project administration</p></fn><fn fn-type="con" id="con15"><p>Resources, Data curation, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Supervision, Funding acquisition, Validation, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: This study was approved by the Institutional Review Board of Shengjing Hospital (approval number: 2020PS014K) and adhered to the principles outlined in the Declaration of Helsinki and Good Clinical Practice. Written informed consent was obtained from all patients.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-83045-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="repstand1"><label>Reporting standard 1.</label><caption><title>STROBE checklist.</title></caption><media xlink:href="elife-83045-repstand1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allred</surname><given-names>DC</given-names></name><name><surname>Anderson</surname><given-names>SJ</given-names></name><name><surname>Paik</surname><given-names>S</given-names></name><name><surname>Wickerham</surname><given-names>DL</given-names></name><name><surname>Nagtegaal</surname><given-names>ID</given-names></name><name><surname>Swain</surname><given-names>SM</given-names></name><name><surname>Mamounas</surname><given-names>EP</given-names></name><name><surname>Julian</surname><given-names>TB</given-names></name><name><surname>Geyer</surname><given-names>CE</given-names></name><name><surname>Costantino</surname><given-names>JP</given-names></name><name><surname>Land</surname><given-names>SR</given-names></name><name><surname>Wolmark</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24</article-title><source>Journal of Clinical Oncology</source><volume>30</volume><fpage>1268</fpage><lpage>1273</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.34.0141</pub-id><pub-id pub-id-type="pmid">22393101</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byun</surname><given-names>DJ</given-names></name><name><surname>Wu</surname><given-names>SP</given-names></name><name><surname>Nagar</surname><given-names>H</given-names></name><name><surname>Gerber</surname><given-names>NK</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Ductal carcinoma in situ in young women: increasing rates of mastectomy and variability in endocrine therapy use</article-title><source>Annals of Surgical Oncology</source><volume>28</volume><fpage>6083</fpage><lpage>6096</lpage><pub-id pub-id-type="doi">10.1245/s10434-021-09972-2</pub-id><pub-id pub-id-type="pmid">33914220</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forbes</surname><given-names>JF</given-names></name><name><surname>Sestak</surname><given-names>I</given-names></name><name><surname>Howell</surname><given-names>A</given-names></name><name><surname>Bonanni</surname><given-names>B</given-names></name><name><surname>Bundred</surname><given-names>N</given-names></name><name><surname>Levy</surname><given-names>C</given-names></name><name><surname>von Minckwitz</surname><given-names>G</given-names></name><name><surname>Eiermann</surname><given-names>W</given-names></name><name><surname>Neven</surname><given-names>P</given-names></name><name><surname>Stierer</surname><given-names>M</given-names></name><name><surname>Holcombe</surname><given-names>C</given-names></name><name><surname>Coleman</surname><given-names>RE</given-names></name><name><surname>Jones</surname><given-names>L</given-names></name><name><surname>Ellis</surname><given-names>I</given-names></name><name><surname>Cuzick</surname><given-names>J</given-names></name><collab>IBIS-II investigators</collab></person-group><year iso-8601-date="2016">2016</year><article-title>Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial</article-title><source>Lancet</source><volume>387</volume><fpage>866</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)01129-0</pub-id><pub-id pub-id-type="pmid">26686313</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganz</surname><given-names>PA</given-names></name><name><surname>Cecchini</surname><given-names>RS</given-names></name><name><surname>Julian</surname><given-names>TB</given-names></name><name><surname>Margolese</surname><given-names>RG</given-names></name><name><surname>Costantino</surname><given-names>JP</given-names></name><name><surname>Vallow</surname><given-names>LA</given-names></name><name><surname>Albain</surname><given-names>KS</given-names></name><name><surname>Whitworth</surname><given-names>PW</given-names></name><name><surname>Cianfrocca</surname><given-names>ME</given-names></name><name><surname>Brufsky</surname><given-names>AM</given-names></name><name><surname>Gross</surname><given-names>HM</given-names></name><name><surname>Soori</surname><given-names>GS</given-names></name><name><surname>Hopkins</surname><given-names>JO</given-names></name><name><surname>Fehrenbacher</surname><given-names>L</given-names></name><name><surname>Sturtz</surname><given-names>K</given-names></name><name><surname>Wozniak</surname><given-names>TF</given-names></name><name><surname>Seay</surname><given-names>TE</given-names></name><name><surname>Mamounas</surname><given-names>EP</given-names></name><name><surname>Wolmark</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial</article-title><source>Lancet</source><volume>387</volume><fpage>857</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)01169-1</pub-id><pub-id pub-id-type="pmid">26686960</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mannu</surname><given-names>GS</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Broggio</surname><given-names>J</given-names></name><name><surname>Charman</surname><given-names>J</given-names></name><name><surname>Cheung</surname><given-names>S</given-names></name><name><surname>Kearins</surname><given-names>O</given-names></name><name><surname>Dodwell</surname><given-names>D</given-names></name><name><surname>Darby</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in england, 1988-2014: population based observational cohort study</article-title><source>BMJ</source><volume>369</volume><elocation-id>m1570</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.m1570</pub-id><pub-id pub-id-type="pmid">32461218</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>G</given-names></name><name><surname>Shi</surname><given-names>XH</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Clinicopathological characteristics of breast ductal carcinoma in situ: an analysis of chinese population of 617 patients</article-title><source>Journal of Oncology</source><volume>2021</volume><elocation-id>8854418</elocation-id><pub-id pub-id-type="doi">10.1155/2021/8854418</pub-id><pub-id pub-id-type="pmid">33488713</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narod</surname><given-names>SA</given-names></name><name><surname>Iqbal</surname><given-names>J</given-names></name><name><surname>Giannakeas</surname><given-names>V</given-names></name><name><surname>Sopik</surname><given-names>V</given-names></name><name><surname>Sun</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Breast cancer mortality after a diagnosis of ductal carcinoma in situ</article-title><source>JAMA Oncology</source><volume>1</volume><fpage>888</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2015.2510</pub-id><pub-id pub-id-type="pmid">26291673</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>C</given-names></name><name><surname>Wobb</surname><given-names>J</given-names></name><name><surname>Manyam</surname><given-names>B</given-names></name><name><surname>Kundu</surname><given-names>N</given-names></name><name><surname>Arthur</surname><given-names>D</given-names></name><name><surname>Wazer</surname><given-names>D</given-names></name><name><surname>Fernandez</surname><given-names>E</given-names></name><name><surname>Vicini</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Management of ductal carcinoma in situ of the breast: a review</article-title><source>JAMA Oncology</source><volume>2</volume><fpage>1083</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2016.0525</pub-id><pub-id pub-id-type="pmid">27253401</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Fuchs</surname><given-names>HE</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cancer statistics, 2021</article-title><source>CA</source><volume>71</volume><fpage>7</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.3322/caac.21654</pub-id><pub-id pub-id-type="pmid">33433946</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wapnir</surname><given-names>IL</given-names></name><name><surname>Dignam</surname><given-names>JJ</given-names></name><name><surname>Fisher</surname><given-names>B</given-names></name><name><surname>Mamounas</surname><given-names>EP</given-names></name><name><surname>Anderson</surname><given-names>SJ</given-names></name><name><surname>Julian</surname><given-names>TB</given-names></name><name><surname>Land</surname><given-names>SR</given-names></name><name><surname>Margolese</surname><given-names>RG</given-names></name><name><surname>Swain</surname><given-names>SM</given-names></name><name><surname>Costantino</surname><given-names>JP</given-names></name><name><surname>Wolmark</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS</article-title><source>Journal of the National Cancer Institute</source><volume>103</volume><fpage>478</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1093/jnci/djr027</pub-id><pub-id pub-id-type="pmid">21398619</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>EM</given-names></name><name><surname>DeSantis</surname><given-names>CE</given-names></name><name><surname>Lin</surname><given-names>CC</given-names></name><name><surname>Kramer</surname><given-names>JL</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Kohler</surname><given-names>B</given-names></name><name><surname>Brawley</surname><given-names>OW</given-names></name><name><surname>Gansler</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cancer statistics: breast cancer in situ</article-title><source>CA</source><volume>65</volume><fpage>481</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.3322/caac.21321</pub-id><pub-id pub-id-type="pmid">26431342</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wärnberg</surname><given-names>F</given-names></name><name><surname>Garmo</surname><given-names>H</given-names></name><name><surname>Emdin</surname><given-names>S</given-names></name><name><surname>Hedberg</surname><given-names>V</given-names></name><name><surname>Adwall</surname><given-names>L</given-names></name><name><surname>Sandelin</surname><given-names>K</given-names></name><name><surname>Ringberg</surname><given-names>A</given-names></name><name><surname>Karlsson</surname><given-names>P</given-names></name><name><surname>Arnesson</surname><given-names>LG</given-names></name><name><surname>Anderson</surname><given-names>H</given-names></name><name><surname>Jirström</surname><given-names>K</given-names></name><name><surname>Holmberg</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized swedcis trial</article-title><source>Journal of Clinical Oncology</source><volume>32</volume><fpage>3613</fpage><lpage>3618</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.56.2595</pub-id><pub-id pub-id-type="pmid">25311220</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Worni</surname><given-names>M</given-names></name><name><surname>Akushevich</surname><given-names>I</given-names></name><name><surname>Greenup</surname><given-names>R</given-names></name><name><surname>Sarma</surname><given-names>D</given-names></name><name><surname>Ryser</surname><given-names>MD</given-names></name><name><surname>Myers</surname><given-names>ER</given-names></name><name><surname>Hwang</surname><given-names>ES</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Trends in treatment patterns and outcomes for ductal carcinoma in situ</article-title><source>Journal of the National Cancer Institute</source><volume>107</volume><elocation-id>djv263</elocation-id><pub-id pub-id-type="doi">10.1093/jnci/djv263</pub-id><pub-id pub-id-type="pmid">26424776</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83045.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pinder</surname><given-names>Sarah</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>King's College London</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.10.06.22280792" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.10.06.22280792"/></front-stub><body><p>This valuable study describes the effects of endocrine therapy in a large series of Chinese patients treated with mastectomy (both efficacy and side effects). Whilst there are some caveats regarding the methodology (retrospective, numbers of events, and some potential methodological bias in data collection) this is an important piece of work and with further, ideally prospective, data collection, has the potential to markedly improve the management of patients with DCIS.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83045.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Pinder</surname><given-names>Sarah</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>King's College London</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Pinder</surname><given-names>Sarah</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>King's College London</institution></institution-wrap><country>United Kingdom</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Dodwell</surname><given-names>David</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0336mm561</institution-id><institution>Oxford University</institution></institution-wrap><country>United Kingdom</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Charan</surname><given-names>Manish</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00rs6vg23</institution-id><institution>The Ohio State University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.10.06.22280792">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2022.10.06.22280792v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Efficacy and safety of endocrine therapy after mastectomy in patients with hormone receptor positive breast ductal carcinoma in situ: retrospective cohort study&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 4 peer reviewers, including Sarah Pinder as Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Tony Ng as the Senior Editor. The following individuals involved in the review of your submission have agreed to reveal their identity: David Dodwell (Reviewer #3); Manish Charan (Reviewer #4).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Detail on the definition and assessment/cut-points for defining hormone receptor positivity should be included.</p><p>2) Comment on the proportion of grades of DCIS would be appropriate, as the distribution is not what one might expect in international series.</p><p>3) The authors should assess what the analysis shows when HR+ DCIS patients with ET after mastectomy are divided into a unilateral mastectomy group vs bilateral mastectomy group to assess whether the effect of ET is different.</p><p>4) The methodology for collecting information on side effects should be described.</p><p>5) The authors should emphasize that this study is retrospective in nature, with a small number of events, and are encouraged to consider (or at least outline the need for) a large, randomized trial in DCIS to better understand the benefits and toxicities of endocrine therapy in DCIS and thus better inform future care.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>More detail on the definition and assessment/cut-points for defining hormone receptor positivity should be included. At present, it is not clear if this means oestrogen or/and progesterone receptor, how this has been assessed, and with what cut-point to define 'positive'. I am not certain if it would be possible to include the degree of positivity in analyses.</p><p>Comment on the proportion of grades of DCIS would be appropriate, as the distribution is not what one might expect and it is not clear why this is so different from what one sees in population series, for example from the UK.</p><p>Similarly, based on the grades reported, the proportion with microinvasive disease is high and the disease-free survival of those with microinvasive disease and in receipt of ET does (non-significantly) seem to show a trend to poorer DFS (Figure 2, D). This might be worthy of further comment.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>The manuscript by Niu and colleagues, entitled &quot;Efficacy and safety of endocrine therapy after mastectomy in patients with hormone receptor positive breast ductal carcinoma in situ: retrospective cohort study.&quot; reported that ET after mastectomy did not prolong the DFS of Chinese HR+ DCIS patients, rather increased adverse effects. For the first time, the authors analyzed beneficial effect and safety of ET after mastectomy in Chinese patients with HR+ DCIS through the clinical case review. The study had a large number of cases, a long follow-up period, a large workload, and a relatively simple research method, which made the results reliable. The conclusion of this study is of great significance to guide the choice of appropriate treatment for Chinese patients with HR+ DCIS, and it has obvious benefits to reduce the economic burden of the patient's family and improve the quality of life for patients. However, there is a question that needs to be considered by the authors: Whether HR+ DCIS patients with ET after mastectomy are divided into unilateral mastectomy group and bilateral mastectomy group to calculate the effect of ET is significantly different.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>I would encourage the authors to consider conducting a large, randomized trial in DCIS to better understand the benefits and toxicities of endocrine therapy in DCIS and thus better inform future care.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83045.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Detail on the definition and assessment/cut-points for defining hormone receptor positivity should be included.</p></disp-quote><p>We are sorry for the confusion. The inclusion criteria included pathological diagnosis of estrogen receptor low-positive (1%-10% nuclei staining) and positive (&gt;10% nuclei staining, using methodology outlined in the ASCO/CAP HR testing guideline) DCIS regardless of progesterone receptor expression. We have added the detailed information on the definition and assessment for defining hormone receptor positivity in the Methods section of the revision (line 96-98). Further stratification analyses indicated the tumor recurrence rate was no significant difference between the ER-low-positive and ER-positive subgroups (P&gt;0.05, Table 3).</p><p>Reference:</p><p>1. Allison Kimberly H, Hammond M Elizabeth H, Dowsett Mitchell et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. [J]. J Clin Oncol, 2020, 38: 1346-1366.</p><disp-quote content-type="editor-comment"><p>2) Comment on the proportion of grades of DCIS would be appropriate, as the distribution is not what one might expect in international series.</p></disp-quote><p>In fact, clinical trials have reported different proportions of grades of DCIS. While 60% of all cases were of high histological grade in UK <sup>1</sup>, the proportion of high histological grade was 34% (206/601) in the Tamoxifen group and 32% (192/592) in the Anastrozole group in the NSABP B-35 study <sup>2</sup>. Furthermore, high histological grade of DCIS accounted for 39% (587/1489) in the Tamoxifen group and 37% (542/1449) in the Anastrozole group in the IBIS-II DCIS trial <sup>3</sup>. A study of Chinese DCIS patients also reported that the percentage of high histological grade of DCIS was 21.9% (135/617) <sup>4</sup>. The proportion of cases with high-grade DCIS in our study (29% vs 24%, respectively) was similarly to other reports.</p><p>Reference:</p><p>1. Mannu, G. S., Wang, Z., Broggio, J., Charman, J., Cheung, S., Kearins, O.,... Darby, S. C. (2020). Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study. <italic>BMJ, 369</italic>, m1570. doi:10.1136/bmj.m1570</p><p>2. Ganz, P. A., Cecchini, R. S., Julian, T. B., Margolese, R. G., Costantino, J. P., Vallow, L. A.,... Wolmark, N. (2016). Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. The Lancet, 387(10021), 857-865. doi:10.1016/s0140-6736(15)01169-1</p><p>3. Forbes, J. F., Sestak, I., Howell, A., Bonanni, B., Bundred, N., Levy, C.,... Cuzick, J. (2016). Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. <italic>The Lancet, 387</italic>(10021), 866-873. doi:10.1016/s0140-6736(15)01129-0</p><p>4. Mao, G., Shi, X., Wang, X., Zhang, X., Chen, X., Ma, J.,... Guo, X. (2021). Clinicopathological Characteristics of Breast Ductal Carcinoma In Situ: An Analysis of Chinese Population of 617 Patients. Journal of oncology, 2021, 8854418. doi:10.1155/2021/8854418</p><disp-quote content-type="editor-comment"><p>3) The authors should assess what the analysis shows when HR+ DCIS patients with ET after mastectomy are divided into a unilateral mastectomy group vs bilateral mastectomy group to assess whether the effect of ET is different.</p></disp-quote><p>There were only sixteen patients, who received bilateral mastectomy. Among the sixteen patients, fifteen received ET and one patient with tumor recurrence in the ET group. Further analyses indicated that the tumor recurrence rate was not significantly different between the unilateral mastectomy group and bilateral mastectomy group [P = 0.54, HR 0.97 (0.95 to 0.98)]. We have added it in the Results section of the revision (line 125-126).</p><disp-quote content-type="editor-comment"><p>4) The methodology for collecting information on side effects should be described.</p></disp-quote><p>The adverse effects were gathered through reviewing the case notes and follow-up records. We have added it in the Methods section of the revision (line 104).</p><disp-quote content-type="editor-comment"><p>5) The authors should emphasize that this study is retrospective in nature, with a small number of events, and are encouraged to consider (or at least outline the need for) a large, randomized trial in DCIS to better understand the benefits and toxicities of endocrine therapy in DCIS and thus better inform future care.</p></disp-quote><p>We recognized that our study was retrospective in nature and with a small number of events. Further validation of these findings is warranted in a large, randomized trial in DCIS to better understand the benefits and toxicities of endocrine therapy in DCIS and better inform future care. In response to his/her concerns, we have discussed the limitation in the revision (line 176-179).</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>More detail on the definition and assessment/cut-points for defining hormone receptor positivity should be included. At present, it is not clear if this means oestrogen or/and progesterone receptor, how this has been assessed, and with what cut-point to define 'positive'. I am not certain if it would be possible to include the degree of positivity in analyses.</p></disp-quote><p>We are sorry for the confusion. The inclusion criteria included pathological diagnosis of estrogen receptor low-positive (1%-10% nuclei staining) and positive (&gt;10% nuclei staining, using methodology outlined in the ASCO/CAP HR testing guideline) DCIS regardless of progesterone receptor expression. We have added the detail information on the definition and assessment for defining hormone receptor positivity in the Methods section of the revision (line 96-98). Further stratification analyses indicated the tumor recurrence rate was not significantly different between the ER-low-positive and ER-positive subgroups (P&gt;0.05, Table 3).</p><p>Reference:</p><p>1. Allison Kimberly H,Hammond M Elizabeth H,Dowsett Mitchell et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.[J].J Clin Oncol, 2020, 38: 1346-1366.</p><disp-quote content-type="editor-comment"><p>Comment on the proportion of grades of DCIS would be appropriate, as the distribution is not what one might expect and it is not clear why this is so different from what one sees in population series, for example from the UK.</p></disp-quote><p>In fact, clinical trials have reported different proportions of grades of DCIS. While 60% of all cases were of high histological grade in UK <sup>1</sup>, the proportion of high histological grade was 34% (206/601) in the Tamoxifen group and 32% (192/592) in the Anastrozole group in the NSABP B-35 study <sup>2</sup>. Furthermore, high histological grade of DCIS accounted for 39% (587/1489) in the Tamoxifen group and 37% (542/1449) in the Anastrozole group in the IBIS-II DCIS trial<sup>3</sup>. A study of Chinese DCIS patients also reported that the percentage of high histological grade of DCIS was 21.9% (135/617) <sup>4</sup>. The proportion of cases with high-grade DCIS in our study (29% vs 24%, respectively) was similarly to other reports.</p><p>Reference:</p><p>1. Mannu, G. S., Wang, Z., Broggio, J., Charman, J., Cheung, S., Kearins, O.,... Darby, S. C. (2020). Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study. BMJ, 369, m1570. doi:10.1136/bmj.m1570</p><p>2. Ganz, P. A., Cecchini, R. S., Julian, T. B., Margolese, R. G., Costantino, J. P., Vallow, L. A.,... Wolmark, N. (2016). Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. The Lancet, 387(10021), 857-865. doi:10.1016/s0140-6736(15)01169-1</p><p>3. Forbes, J. F., Sestak, I., Howell, A., Bonanni, B., Bundred, N., Levy, C.,... Cuzick, J. (2016). Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. The Lancet, 387(10021), 866-873. doi:10.1016/s0140-6736(15)01129-0</p><p>4. Mao, G., Shi, X., Wang, X., Zhang, X., Chen, X., Ma, J.,... Guo, X. (2021). Clinicopathological Characteristics of Breast Ductal Carcinoma In Situ: An Analysis of Chinese Population of 617 Patients. Journal of oncology, 2021, 8854418. doi:10.1155/2021/8854418</p><disp-quote content-type="editor-comment"><p>Similarly, based on the grades reported, the proportion with microinvasive disease is high and the disease-free survival of those with microinvasive disease and in receipt of ET does (non-significantly) seem to show a trend to poorer DFS (Figure 2, D). This might be worthy of further comment.</p></disp-quote><p>The proportion with microinvasive DCIS was 16% in the ET group, and 13% in the non-ET group, respectively. Further analysis indicated that patients with high grade of DCIS in the microinvasive subgroup accounted for 42% and 10% in the ET group and non-ET group, respectively. This might explain why the DFS of those with microinvasive DCIS in the ET group trended to be worse than those in the non-ET group although there was no significant difference between them. We have discussed this point in the section of Discussion (line 156-161).</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>The manuscript by Niu and colleagues, entitled &quot;Efficacy and safety of endocrine therapy after mastectomy in patients with hormone receptor positive breast ductal carcinoma in situ: retrospective cohort study.&quot; reported that ET after mastectomy did not prolong the DFS of Chinese HR+ DCIS patients, rather increased adverse effects. For the first time, the authors analyzed beneficial effect and safety of ET after mastectomy in Chinese patients with HR+ DCIS through the clinical case review. The study had a large number of cases, a long follow-up period, a large workload, and a relatively simple research method, which made the results reliable. The conclusion of this study is of great significance to guide the choice of appropriate treatment for Chinese patients with HR+ DCIS, and it has obvious benefits to reduce the economic burden of the patient's family and improve the quality of life for patients. However, there is a question that needs to be considered by the authors: Whether HR+ DCIS patients with ET after mastectomy are divided into unilateral mastectomy group and bilateral mastectomy group to calculate the effect of ET is significantly different.</p></disp-quote><p>There were only sixteen patients, who received bilateral mastectomy. Among the sixteen patients, fifteen received ET and one patient with tumor recurrence in the ET group. Further analyses indicated that the tumor recurrence rate was not significantly different between the unilateral mastectomy group and bilateral mastectomy group [P = 0.54, HR 0.97 (0.95 to 0.98)]. We have added it in the Results section of the revision (line 125-126).</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>I would encourage the authors to consider conducting a large, randomized trial in DCIS to better understand the benefits and toxicities of endocrine therapy in DCIS and thus better inform future care.</p></disp-quote><p>We recognized that our study was retrospective in nature and with a small number of events. Further validation of these findings is warranted in a large, randomized trial in DCIS to better understand the benefits and toxicities of endocrine therapy in DCIS and better inform future care. In response to his/her concerns, we have discussed the limitations in the revision (line 176-179).</p></body></sub-article></article>